This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grossfeld, P. Search for Related Content PubMed PubMed Citation Articles by Grossfeld, P.

(Circulation Research. 2007;100:1246.)
© 2007 American Heart Association, Inc.

Editorials

Hypoplastic Left Heart Syndrome

New Insights

Paul Grossfeld

From the Division of Pediatric Cardiology, UCSD School of Medicine.

Correspondence to Paul Grossfeld, MD, University of California, San Diego, Division of Pediatric Cardiology, 9500 Gilman Drive # 0831, La Jolla, CA 92093-0831. E-mail pgrossfeld@ucsd.edu

See related article, pages 1363–1370

Key Words: hypoplastic left heart syndrome • myocyte hyperplasia • two-ventricle repair

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Hypoplastic left heart syndrome (HLHS) is one of the most severe congenital heart defects, accounting for 20% to 25% of mortality in infants born with congenital heart disease. In the United States, 2000 infants are born each year with HLHS.¹ To date, there is a paucity of studies that define the underlying genetic, molecular and cellular mechanisms of HLHS.^2–4

Most cases of HLHS are thought to arise secondarily because of decreased flow into the developing embryonic left ventricle, although in some cases, abnormal left ventricular growth could be the primary defect. There is strong evidence for a genetic etiology for HLHS, although very little is understood about the genetic mechanisms underlying HLHS. Nineteen percent of first degree relatives of infants with HLHS have a congenital heart defect.⁵ In addition, there are several chromosomal disorders that are associated with HLHS. For example, 10% of all infants born with a terminal 11q deletion (Jacobsen syndrome) have HLHS.⁶ Mutations in at least one gene, the cardiac transcription factor NKX2.5, have been identified in patients with HLHS.^7,8

Similar to many of the most severe congenital heart defects, treatment strategies for HLHS have evolved and are still changing. The two current surgical strategies include the three-stage Norwood/Fontan procedure, or, alternatively, cardiac transplantation. The Norwood procedure, which is performed optimally in the neonatal period to avoid the development of pulmonary vascular disease, entails reconstructing the aortic arch, transecting the pulmonary artery, anastamosing the pulmonary artery root to the reconstructed aorta, and placing a systemic to pulmonary . . . [Full Text of this Article]

This article has been cited by other articles:

				P. D. Grossfeld Hypoplastic Left Heart Syndrome: It Is All in the Genes J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1596 - 1597. [Full Text] [PDF]